Comparative analysis on renal and cardiovascular outcomes of antidiabetic treatment in chronic kidney disease patients—A systematic review and network meta‐analysis
SGLT2 inhibitors followed by GLP-1 RA provide strong benefits for CV and kidney health in patients with T2DM and CKD. SGLT2 inhibitors demonstrate superior benefit over GLP-1 receptor agonists for HF and renal outcomes, highlighting their preferred role in these clinical scenarios.
Authors
- Treesa P. Varghese (ORCID: https://orcid.org/0000-0002-8337-319X)
- Stefanie Lanzinger (ORCID: https://orcid.org/0000-0002-3789-6459)
- Peter Bramlage (ORCID: https://orcid.org/0000-0003-4970-2110)
- Anjaly Vijayan (ORCID: https://orcid.org/0009-0009-0915-427X)
- Deepthy Melepurakkal Sadanandan (ORCID: https://orcid.org/0000-0001-8547-2901)
- Cristina Rodríguez (ORCID: https://orcid.org/0000-0003-3954-0736)
Institutions
- Yenepoya University (IN)
- Universität Ulm (DE)
- IPPMed (Germany) (DE)
- Zimmer Biomet (Germany) (DE)
- Jawaharlal Nehru Medical College (IN)
- KLE Academy of Higher Education and Research (IN)
- Deutsches Diabetes-Zentrum e.V. (DE)
- German Center for Diabetes Research (DE)
- Heinrich Heine University Düsseldorf (DE)
- Universidad de Sevilla (ES)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1111/dom.70010
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29